Compare DXR & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXR | GROV |
|---|---|---|
| Founded | 1970 | 2016 |
| Country | United States | United States |
| Employees | N/A | 295 |
| Industry | Medical/Dental Instruments | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 52.1M |
| IPO Year | 1995 | N/A |
| Metric | DXR | GROV |
|---|---|---|
| Price | $10.45 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.60 |
| AVG Volume (30 Days) | 1.8K | ★ 43.8K |
| Earning Date | 02-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | $6.81 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $1.05 |
| 52 Week High | $14.76 | $1.60 |
| Indicator | DXR | GROV |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 40.68 |
| Support Level | $9.35 | $1.07 |
| Resistance Level | $10.91 | $1.33 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 20.83 | 12.50 |
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.